Q32 Bio (QTTB) SIGNAL-AD trial did not achieve its primary endpoint, SIGNAL-AA demonstrated encouraging clinical activity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. EXC
5. SKA-B
6. PBA
7. CCH:LN
8. META
9. BAJAJHFL:I
10. CCHGY

Go back to Q32 Bio (QTTB) SIGNAL-AD trial did not achieve its primary endpoint, SIGNAL-AA demonstrated encouraging clinical activity

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

December 10, 2024 4:05 PM EST

-- SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 response --

-- SIGNAL-AD Phase 2a clinical trial in atopic dermatitis demonstrated promising findings in Part A but did not meet primary endpoint in Part B --

-- Across both trials, bempikibart was observed to be safe and well tolerated; demonstrated potent IL-7 and TSLP inhibition via changes in both Th2 biomarkers and T-cells, and desired target... More